Hypertension Control in Pregnancy

Poll

Which of the following statements regarding the treatment of hypertension in pregnancy are true?

A. With preeclampsia and severe hypertension pre-delivery, parenteral nifedipine, labetalol, or hydralazine may be used.
B. ACE inhibitor use during pregnancy has been associated with oligohydramnios, fetal renal dysfunction, and fetal death.
C. Labetalol may aggravate bradycardia and/or asthma.
Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Axsome Completes Phase 3 Clinical Program with AXS-05 in Alzheimer Disease Agitation / image credit Jeffrey L Cummings, MD, ScD, Courtesy of UNLV

Axsome Completes Phase 3 Clinical Program with AXS-05 in Alzheimer Disease Agitation

Grace Halsey
January 2nd 2025
Article

Axsome plans to submit a New Drug Application to the FDA in the second half of 2025 that is based on positive results from 4 pivotal phase 3 clinical trails and long-term data.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Upadacitinib Shows Long-Term Efficacy in Adolescent Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock

Upadacitinib Shows Long-Term Efficacy in Adolescent Atopic Dermatitis: Daily Dose

Sydney Jennings
December 24th 2024
Article

Your daily dose of the clinical news you may have missed.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose / image credit: ©New Africa/AdobeStock

New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose

Sydney Jennings
December 23rd 2024
Article

Your daily dose of the clinical news you may have missed.

FDA Adds Black Box Warning to Fezolinetant Label, Advising of Rare but Serious Liver Injury / image credit ©Jerome/stock.adobe.com

FDA Adds Black Box Warning to Fezolinetant Label, Advising of Rare but Serious Liver Injury

Grace Halsey
December 23rd 2024
Article

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

© 2025 MJH Life Sciences

All rights reserved.